Has Sara McCoy, MD received payments from drug or device companies?

Yes. Drug and device makers reported $79,906 in general payments to Sara McCoy, MD across 37 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Sara McCoy, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Sara McCoy, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Sara McCoy, MD

Rheumatology · Madison, WINPI 1639480650

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $72,164 of the $79,906 with a category attached, or 90.3%. Novartis accounts for 64.2% of it on its own, with 8 other manufacturers making up the rest. 2025 is the largest year on record at $29,673, more than ten times the $2,020 reported in 2020. Among rheumatology clinicians in WI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$79,906in general payments, 2019–2025

Across 37 payments — averaging $2159.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novartis$51K
Otsuka Pharmaceutical Development & Commercialization, Inc.$11K
Amgen$7K
E.r. Squibb & Sons, L.L.C.$5K
Aurinia Pharma U.S., Inc.$2K
Janssen Research & Development, LLC$2K
plus $2K from 3 others

$308,782in research payments, 2019–2025

Across 18 payments — averaging $17,155 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Novartis$195K
Amgen$104K
E.r. Squibb & Sons, L.L.C.$10K

What the payments were for

Consulting fees$72,16490%
Speaking & faculty fees$4,7346%
Grants$1,2002%
Travel & lodging$1,2142%
Food & beverage$5941%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novartis	20	$51,319
Otsuka Pharmaceutical Development & Commercialization, Inc.	6	$11,465
Amgen(2 entities)	3	$6,731
E.r. Squibb & Sons, L.L.C.	1	$4,734
Aurinia Pharma U.S., Inc.	1	$2,200
Janssen Research & Development, LLC	3	$1,890
Boehringer Ingelheim	1	$870
Kiniksa Pharmaceuticals International, PLC	1	$597
Johnson & Johnson	1	$100

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

COSENTYX$2,444
LUPKYNIS$2,200
Tremfya$100

How this compares

$79,906 in reported general payments places this provider in the 90th percentile of 120 rheumatology providers in Wisconsin.

See all rheumatology providers in Wisconsin →

Medicare billing

Part B allowed, 2024

$14,481

Medicare patients

103

Services billed

232

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Cevimeline Hcl	56	$16,812
PlaquenilHydroxychloroquine Sulfate	12	$13,566
Hydroxychloroquine Sulfate	159	$5,712
MethotrexateMethotrexate Sodium	44	$995
Leflunomide	13	$666
Prednisone	71	$614
Celecoxib	22	$429
Clotrimazole	13	$367
Alendronate Sodium	21	$287
Colchicine	15	$225
Sodium Fluoride 5000 PlusFluoride (Sodium)	20	$195
Methotrexate SodiumMethotrexate Sodium/Pf	12	$178
Allopurinol	11	$119

Paid to pharmacies, not to this prescriber.

Other rheumatology in Madison

Fardina MalikMadison$17K
Michael WalshMadison$16K
Tiffany LinMadison$5K
Carmen CampbellMadison$5K
Jilaine Bolek BerquistMadison$2K
John JuozeviciusMadison$1K
Kurt OelkeGlendale$750K
Daniel MaloneBeaver Dam$505K
John AlbertGlendale$369K
Taraneh MehraniMenomonee Falls$176K

See the full list for Wisconsin →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →